CN109223890A - A kind of composition for premature ejaculation sex dysfunction - Google Patents
A kind of composition for premature ejaculation sex dysfunction Download PDFInfo
- Publication number
- CN109223890A CN109223890A CN201710557763.XA CN201710557763A CN109223890A CN 109223890 A CN109223890 A CN 109223890A CN 201710557763 A CN201710557763 A CN 201710557763A CN 109223890 A CN109223890 A CN 109223890A
- Authority
- CN
- China
- Prior art keywords
- parts
- premature ejaculation
- composition
- sex dysfunction
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010036596 premature ejaculation Diseases 0.000 title claims abstract description 51
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 230000004064 dysfunction Effects 0.000 title claims abstract description 23
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000003814 drug Substances 0.000 claims abstract description 24
- 241000255789 Bombyx mori Species 0.000 claims abstract description 15
- 241000269420 Bufonidae Species 0.000 claims abstract description 15
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 241000628997 Flos Species 0.000 claims abstract description 15
- 229960003260 chlorhexidine Drugs 0.000 claims abstract description 15
- 229960000278 theophylline Drugs 0.000 claims abstract description 15
- 239000002435 venom Substances 0.000 claims abstract description 15
- 210000001048 venom Anatomy 0.000 claims abstract description 15
- 231100000611 venom Toxicity 0.000 claims abstract description 15
- 235000014220 Rhus chinensis Nutrition 0.000 claims abstract description 13
- 240000003152 Rhus chinensis Species 0.000 claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 239000004475 Arginine Substances 0.000 claims abstract description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000000284 extract Substances 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 16
- 238000000605 extraction Methods 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 6
- 239000000470 constituent Substances 0.000 claims description 4
- 230000036299 sexual function Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 12
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 235000019441 ethanol Nutrition 0.000 description 12
- 238000002386 leaching Methods 0.000 description 12
- 238000000034 method Methods 0.000 description 10
- 230000001568 sexual effect Effects 0.000 description 9
- 238000001035 drying Methods 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 5
- 229960001631 carbomer Drugs 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 4
- 229930064664 L-arginine Natural products 0.000 description 4
- 235000014852 L-arginine Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 206010041497 Spermatorrhoea Diseases 0.000 description 2
- 238000009227 behaviour therapy Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000009329 sexual behaviour Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960001807 prilocaine Drugs 0.000 description 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008783 wuzi yanzong Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/65—Amphibians, e.g. toads, frogs, salamanders or newts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/758—Zanthoxylum, e.g. pricklyash
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Insects & Arthropods (AREA)
- Urology & Nephrology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of compositions for premature ejaculation sex dysfunction, it is made of Chlorhexidine, the dried venom of toads, male silk moth, pericarpium zanthoxyli, ramulus cinnamomi, flos caryophylli, Chinese gall, frutus cnidii, theophylline, arginine and/or citrulling can also be added, composition of the invention can be used for being prepared into drug, health care product or sanitizer preparation appropriate, be widely used in the andrology's health care of premature ejaculation sex dysfunction and disease treatment scope.
Description
Technical field
The present invention relates to a kind of composition for premature ejaculation sex dysfunction, composition of the invention can be used for being prepared into suitable
When drug, health care product or sanitizer preparation, be widely used in the andrology's health care of premature ejaculation sex dysfunction and disease treatment scope.
Background technique
Influence of the premature ejaculation to male patient: premature ejaculation (PE) is one of most common sex dysfunction of male, often in insertion yin
Road occurs in 2 minutes, and patient cannot mostly extend the ejaculation time.Premature ejaculation disease incidence is higher, national of the United States's health and social life
Investigation display, in 18-59 years old male, premature ejaculation illness rate is 31%.One questionnaire survey of Britain shows, premature ejaculation
Illness rate is 14%；The investigation of France shows that the lifetime prevalence of premature ejaculation is 15%；Italian questionnaire survey, premature ejaculation illness rate are
21%.With the variation of people's attitude towards sex, influence of the PE to patient and companion's quality of life is increasingly subject to the attention of people, premature ejaculation
It can lead to depressed patient mental, anxiety, depression etc., influence the relationship of sexual desire prestige, delight of life and companion.In addition to Patients with Premature Ejaculation,
Also wish to promote life quality by extending the sexual behaviour time, promote companionship there are also considerable normal male.Extend
The sexual life time is not only the great demand of numerous PE patients and numerous males.
The treatment of premature ejaculation: the treatment method of premature ejaculation is more, including psychotherapy, behaviour therapy, oral drug therapy, negative pressure
Numerous methods such as attraction, drug injection, surgical operation and external medication.Because external drug is easily operated, malaise symptoms
Less, the features such as other treatment method can be cooperated, treatment method acceptance level of the PE patient to external drug extending sex time
Height, clinically common external application delay powder object is mainly Western medicine at present, there is one lidocaine latex of prilocaine or spraying, Ding Ka
Because of paste, lidocaine gel etc., by making the mucocutaneous sensibility reduction to feeling achieve the purpose that improve premature ejaculation symptom.
In PE treatment, sexual behaviour treatment is Primary Care method, higher in external development degree, but degree is carried out in domestic behaviour therapy
Low, lacking assistant product is one of reason.
Understanding of the Chinese medicine to premature ejaculation: traditional Chinese medicine records " all pathogeny times that Sui's Chao Yuanfang (550-630 A.D.) can be traced to premature ejaculation earliest
By ", propose that " the excessive smart information essence of consumptive disease goes out to wait: kidney qi is weak, therefore spermatorrhea.Information thoughts and feelings then moves kidney qi, and kidney storing essence is modern weak
It cannot be formed on essence, therefore spermatorrhea goes out due to information." but until the Qing Dynasty, doctor's Chen Shiduo in " dialectical record kind heir door " for the first time
" premature ejaculation " word is used.Traditional Chinese medicine thinks, though the hiding of essence let out system in kidney, it is so in close relations with the heart, liver, spleen.The hair of premature ejaculation
Raw odd with above-mentioned Zang-Fu relationship rice, pathologic feature is divided into actual situation, but simulataneous insufficiency and excessive is clinical more common.
The Chinese medicine external agent of premature ejaculation is treated: Chinese traditional treatment premature ejaculation method is more, and oral medicinal herb is one of major way, mainly
Based on help class Chinese medicine, the help to liver kidney is stressed in particular, it is more famous such as classical prescription wuzi yanzong pills.In addition in
Medicine is for oral administration, and there are also external therapy treatment premature ejaculation or enhancing ability, extending sex times for Chinese medicine, and form convenience, therapy are only
The methods of spy, predominantly acupuncture and tuina-massage, Chinese medicine external.A large amount of clinical experiences show that Chinese medicine external extends sexual life for PE patient
Chronergy is good.
It can be a long-term trend from botanical medicine developing products so complying with PE demand and demand for security, so this
The research of composition has the meaning for complying with green demand and natural safety.
Goal of the invention: the object of the present invention is to provide one kind safely and effectively, is easy by primary raw material, people of crude drug
The composition of a kind of premature ejaculation sex dysfunction andrology's health care and disease treatment that receive.
Composition material for premature ejaculation sex dysfunction of the invention, is mentioned by conventional and/or unconventional extraction means
The active constituent for taking medicinal material is prepared into drug, health care product or sanitizer preparation appropriate, protects for premature ejaculation sex dysfunction andrology
Strong and disease treatment, is played a role by the principle of external treatment with Chinese medicine, is used for a long time safely and effectively, is complied fully with green demand, institute
Also there is apparent innovative and industrialization social benefit with this composition.
Summary of the invention
In order to achieve the above object, solution adopted by the present invention is:
The specific method is as follows:
A kind of composition for premature ejaculation sex dysfunction, is made of following weight raw material: 1~5 part of Chlorhexidine, the dried venom of toads 1~5
Part, 5~10 parts of male silk moth, 5~10 parts of pericarpium zanthoxyli, 5~15 parts of ramulus cinnamomi, 5~10 parts of flos caryophylli, 5~10 parts of Chinese gall, frutus cnidii 5
~10 parts, 1~3 part of theophylline.
The composition for premature ejaculation sex dysfunction, also containing weight raw material arginine and/or citrulling each 1~
3 parts.
A kind of composition for premature ejaculation sex dysfunction, medicinal material pass through conventional and/or unconventional extraction means
Extract the active constituent of medicinal material.
A kind of composition for premature ejaculation sex dysfunction, active constituent are prepared into drug appropriate, health care product
Or sanitizer preparation.
A kind of composition for premature ejaculation sex dysfunction, be mainly used for the andrology's health care of premature ejaculation sex dysfunction and
Disease treatment scope.
The beneficial technical effect of the present composition:
(1) composition of the present invention by reducing the susceptibility of nerve, but does not reduce voluptus, for premature ejaculation
Sex dysfunction.
(2) composition of the present invention, it is quality controllable, it is safe and convenient to use.
(3) composition of the present invention, is suitable for industrialized production.
The characteristics of present composition:
(1) based on natural plants and animal drug, natural activity.
(2) treating both manifestation and root cause of disease, pharmacological property are mildly safe.
(3) susceptibility of nerve is reduced, but does not reduce voluptus.
Specific embodiment
The following is a clear and complete description of the technical scheme in the embodiments of the invention, it is clear that described embodiment
Only a part of the embodiment of the present invention, instead of all the embodiments.Based on the embodiment of the present invention, ordinary skill
Personnel's all other embodiment obtained without making creative work, belongs to protection scope of the present invention.
Therapeutic effect of 1. present composition of embodiment for premature ejaculation
(1) volunteer's inclusion criteria
1. 18-50 years old male of patient age.
2. keeping sexual intercourse at least six of single stable more than the moon with same women.
3. meeting PE diagnosis mark in " the mental disease diagnostic and statistical manual-fourth edition " of Americanism disease society of america promulgation
It is quasi-.
(2) therapeutic scheme
Treatment group: present composition exterior-applied gel, totally 40.
Control group: totokaine rubber cement group, totally 40.
(3) administrated method
Two groups of equal external applications, half an hour uses before sexual intercourse, forbids drug combination, and the course for the treatment of 4 weeks.Two groups of medications are taken, glans penis is applied to
The positions such as surface, coronary sulcus and bridle of prepuce, it is desirable that smear uniformly, and absorbed naturally to it, use clear water before carrying out sexual life
It has sexual intercourse again after cleaning.It is required that Regularity of sexual activity is 3 days 1 time, sexual life environment is good, and both sides are full of physical strength.
(4) treatment results
Pretherapy and post-treatment 2 weeks of 1 two groups of volunteers of table and 4 weeks ILET compare
| Group | Quantity (example) | Before treatment | 2 weeks after treatment | 4 weeks after treatment |
| Treatment group | 40 | 0.59±0.10 | 3.98±1.11 | 4.32±1.47 |
| Control group | 40 | 0.58±0.11 | 3.52±1.12 | 3.61±1.38 |
Note: 1. two groups of ejaculation latencies after the treatment are obviously prolonged earlier above.
2. two groups have notable difference, P < 0.05 compared with before and after treatment respectively.
3. there are notable difference, P < 0.05 in treatment group compared with the pretherapy and post-treatment average ejaculation latency of control group.
Pretherapy and post-treatment 2 weeks of 2 two groups of volunteers of table and 4 weeks ILET compare
| Group | Quantity (example) | Before treatment | 2 weeks after treatment | 4 weeks after treatment |
| Treatment group | 40 | 9.2±1.32 | 15.5±1.65 | 15.7±1.54 |
| Control group | 40 | 8.9±1.51 | 11.5±1.38 | 11.8±1.27 |
Note: there are significant difference, P < 0.05 compared with treatment group's sexual intercourse satisfaction scoring (SSS) pretherapy and post-treatment with control group.
2. prescription of embodiment: 1 part of Chlorhexidine, 1 part of the dried venom of toads, 5 parts of male silk moth, 5 parts of pericarpium zanthoxyli, 5 parts of ramulus cinnamomi, 5 parts of flos caryophylli, five
5 parts of gall nut, 5 parts of frutus cnidii, 1 part of theophylline.
Step 1 takes the dried venom of toads, male silk moth, pericarpium zanthoxyli, ramulus cinnamomi, flos caryophylli, Chinese gall, frutus cnidii, with 5 times of 75% ethyl alcohol, 50 DEG C
It extracts refluxing extraction 2.0 hours, extracts 1 time, filter to obtain leaching liquor, leaching liquor recycles ethyl alcohol, and drying and crushing was both extracted
Object.
Step 2, the extract for taking step 1 are added chlorhexidine, theophylline, mix well, and both obtain mixed material.
10 times of inventory of solvent is added in step 3, the mixed material for taking step 2, and 0.3% carbomer of total volume is added, fills
Divide and mix, adjusts pH value to 5.0-7.0 to get the gel of the present composition.
3. prescription of embodiment: 2 parts of Chlorhexidine, 3 parts of the dried venom of toads, 7 parts of male silk moth, 7 parts of pericarpium zanthoxyli, 10 parts of ramulus cinnamomi, 7 parts of flos caryophylli,
7 parts of Chinese gall, 7 parts of frutus cnidii, 2 parts of theophylline.
Step 1 takes the dried venom of toads, male silk moth, pericarpium zanthoxyli, ramulus cinnamomi, flos caryophylli, Chinese gall, frutus cnidii, with 5 times of 85% ethyl alcohol, 50 DEG C
It extracts refluxing extraction 1.5 hours, extracts 1 time, filter to obtain leaching liquor, leaching liquor recycles ethyl alcohol, and drying and crushing was both extracted
Object.
Step 2, the extract for taking step 1 are added chlorhexidine, theophylline, mix well, and both obtain mixed material.
8 times of inventory of solvent is added in step 3, the mixed material for taking step 2,0.8% carbomer of total volume is added, sufficiently
It mixes, adjusts pH value to 5.0-7.0 to get the gel of the present composition.
4. prescription of embodiment: 3 parts of Chlorhexidine, 5 parts of the dried venom of toads, 10 parts of male silk moth, 10 parts of pericarpium zanthoxyli, 15 parts of ramulus cinnamomi, flos caryophylli 10
Part, 10 parts of Chinese gall, 10 parts of frutus cnidii, 3 parts of theophylline.
Step 1 takes the dried venom of toads, male silk moth, pericarpium zanthoxyli, ramulus cinnamomi, flos caryophylli, Chinese gall, frutus cnidii, with 5 times of 95% ethyl alcohol, 50 DEG C
It extracts refluxing extraction 1.0 hours, extracts 1 time, filter to obtain leaching liquor, leaching liquor recycles ethyl alcohol, and drying and crushing was both extracted
Object.
Step 2, the extract for taking step 1 are added chlorhexidine, theophylline, mix well, and both obtain mixed material.
6 times of inventory of solvent is added in step 3, the mixed material for taking step 2,1.0% carbomer of total volume is added, sufficiently
It mixes, adjusts pH value to 5.0-7.0 to get the gel of the present composition.
5. prescription of embodiment: 1 part of Chlorhexidine, 1 part of the dried venom of toads, 5 parts of male silk moth, 5 parts of pericarpium zanthoxyli, 5 parts of ramulus cinnamomi, 5 parts of flos caryophylli, five
5 parts of gall nut, 5 parts of frutus cnidii, 1 part of theophylline, 1 part of L-arginine.
Step 1 takes the dried venom of toads, male silk moth, pericarpium zanthoxyli, ramulus cinnamomi, flos caryophylli, Chinese gall, frutus cnidii, with 5 times of 75% ethyl alcohol, 50 DEG C
It extracts refluxing extraction 3.0 hours, extracts 1 time, filter to obtain leaching liquor, leaching liquor recycles ethyl alcohol, and drying and crushing was both extracted
Object.
Step 2, the extract for taking step 1 are added chlorhexidine, theophylline, 1 part of L-arginine, mix well, and both obtain mixture
Material.
Step 3, the mixed material for taking step 2 are added 10 times of inventory of solvent, mix well, and adjust pH value to 5.0-
7.0 to get the present composition spray.
6. prescription of embodiment: 2 parts of Chlorhexidine, 3 parts of the dried venom of toads, 7 parts of male silk moth, 7 parts of pericarpium zanthoxyli, 10 parts of ramulus cinnamomi, 7 parts of flos caryophylli,
7 parts of Chinese gall, 7 parts of frutus cnidii, 2 parts of theophylline, 1 part of citrulling.
Step 1 takes the dried venom of toads, male silk moth, pericarpium zanthoxyli, ramulus cinnamomi, flos caryophylli, Chinese gall, frutus cnidii, with 5 times of 85% ethyl alcohol, 50 DEG C
It extracts refluxing extraction 1.5 hours, extracts 1 time, filter to obtain leaching liquor, leaching liquor recycles ethyl alcohol, and drying and crushing was both extracted
Object.
Step 2, the extract for taking step 1 are added chlorhexidine, theophylline, citrulling, mix well, and both obtain mixed material.
8 times of inventory of solvent is added in step 3, the mixed material for taking step 2,0.5% carbomer of total volume is added, sufficiently
It mixes, adjusts pH value to 5.0-7.0 to get the liniment of the present composition.
7. prescription of embodiment: 3 parts of Chlorhexidine, 5 parts of the dried venom of toads, 10 parts of male silk moth, 10 parts of pericarpium zanthoxyli, 15 parts of ramulus cinnamomi, flos caryophylli 10
Part, 10 parts of Chinese gall, 10 parts of frutus cnidii, 3 parts of theophylline, 3 parts of L-arginine, 3 parts of citrulling.
Step 1 takes the dried venom of toads, male silk moth, pericarpium zanthoxyli, ramulus cinnamomi, flos caryophylli, Chinese gall, frutus cnidii, with 5 times of 95% ethyl alcohol, 50 DEG C
It extracts refluxing extraction 1.0 hours, extracts 1 time, filter to obtain leaching liquor, leaching liquor recycles ethyl alcohol, and drying and crushing was both extracted
Object.
Step 2, the extract for taking step 1 are added chlorhexidine, theophylline, L-arginine, citrulling, mix well, must both mix
Close material.
6 times of inventory of solvent is added in step 3, the mixed material for taking step 2,1.0% carbomer of total volume is added, sufficiently
It mixes, adjusts pH value to 5.0-7.0 to get the gel of the present composition.
Have effects that in combinations of the above object for the andrology's health care of premature ejaculation sex dysfunction and disease treatment.
This composition and similar condition ratio, raw material chemicals of the present invention are of fine quality to be easy to get, curative for effect, has letter
Efficiently, safely, and the advantage that cost is relatively low, easy to operate, replicability is strong, application prospect is extensive just,.
The foregoing is only a preferred embodiment of the present invention, but scope of protection of the present invention is not limited thereto,
Within the technical scope of the present disclosure, any changes or substitutions that can be easily thought of by anyone skilled in the art,
It should be covered by the protection scope of the present invention.Therefore, protection scope of the present invention should be with the protection model of claims
Subject to enclosing.
Claims (5)
1. a kind of composition for premature ejaculation sex dysfunction, is made of following weight raw material: 1~5 part of Chlorhexidine, the dried venom of toads 1~5
Part, 5~10 parts of male silk moth, 5~10 parts of pericarpium zanthoxyli, 5~15 parts of ramulus cinnamomi, 5~10 parts of flos caryophylli, 5~10 parts of Chinese gall, frutus cnidii 5
~10 parts, 1~3 part of theophylline.
2. being used for the composition of premature ejaculation sex dysfunction described in claim 1, it is characterised in that: also contain weight raw material arginine
And/or each 1~3 part of citrulling.
3. a kind of composition for premature ejaculation sex dysfunction described in claim 1, it is characterised in that: by conventional and/or
Unconventional extraction means extract the active constituent of medicinal material.
4. a kind of composition for premature ejaculation sex dysfunction described in claim 1, it is characterised in that: be prepared into medicine appropriate
Object, health care product or sanitizer preparation.
5. a kind of composition for premature ejaculation sex dysfunction described in claim 1, it is characterised in that: be used for premature ejaculation sexual function
The health care of obstacle andrology and disease treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710557763.XA CN109223890A (en) | 2017-07-10 | 2017-07-10 | A kind of composition for premature ejaculation sex dysfunction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710557763.XA CN109223890A (en) | 2017-07-10 | 2017-07-10 | A kind of composition for premature ejaculation sex dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109223890A true CN109223890A (en) | 2019-01-18 |
Family
ID=65083601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710557763.XA Pending CN109223890A (en) | 2017-07-10 | 2017-07-10 | A kind of composition for premature ejaculation sex dysfunction |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109223890A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111658675A (en) * | 2020-06-16 | 2020-09-15 | 欧阳志华 | Composition for treating male sexual function and preparation method thereof |
-
2017
- 2017-07-10 CN CN201710557763.XA patent/CN109223890A/en active Pending
Non-Patent Citations (5)
| Title |
|---|
| 崔振泽等: "《儿科常用药物解析》", 30 April 2015, 辽宁科学技术出版社 * |
| 张揆一等: "《老年婚姻与性生活咨询》", 28 February 2003, 金盾出版社 * |
| 桑爱军等: "《男性不育诊疗指南》", 30 November 2010, 中国医药科技出版社 * |
| 王福: "五丁延时喷雾剂之劳原发性早泄的随机对照临床观察", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
| 鲁兆麟等: "《中医各家学说》", 31 July 2005, 中国协和医科大学出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111658675A (en) * | 2020-06-16 | 2020-09-15 | 欧阳志华 | Composition for treating male sexual function and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109223890A (en) | A kind of composition for premature ejaculation sex dysfunction | |
| CN103768357B (en) | A kind of Traditional Chinese medicine compound composition with treatment recurrent aphtha | |
| CN102670945B (en) | Prunella vulgaris traditional Chinese medicine oral liquid for adjuvant therapy of pleurisy and preparation method thereof | |
| CN100364587C (en) | Acupoint selection strapping medicine for treating chronic bronchitis and bronchial asthma and its compounding method | |
| CN1294930C (en) | Medication for treating cough caused by inflammation of upper respiratory tract | |
| CN108324815A (en) | A kind of composition for sex dysfunctions such as prospermia of males | |
| CN101874864B (en) | Chinese traditional medicament for treating cervical vertigo diseases | |
| CN101129637A (en) | Traditional Chinese Medicine for Treating Vascular Headache | |
| CN101474267B (en) | Medicament for treating psychasthenia, insomnia, vexation, encephalatrophy and dementia | |
| CN104666516A (en) | Anti-inflammatory leucorrhoea arresting washing liquor | |
| CN102648956A (en) | Traditional Chinese herbal medicament for treating breast cancer and preparation method thereof | |
| CN107714995A (en) | A kind of Chinese medicine for treating hemorrhoid | |
| CN102755607B (en) | Medicine for treating bronchitis and asthma and preparation method thereof | |
| CN101829162A (en) | Pharmaceutical composition for treating allergic rhinitis and preparation method thereof | |
| CN101390992B (en) | Asthma oral liquid and its preparing process | |
| CN102813888A (en) | Chinese herbal composition for treating epilepsy | |
| CN102526570A (en) | Foot bath Chinese medicinal composition for treating cough | |
| CN107875256A (en) | A kind of strong medicine point-application drug paste for the treatment of of insomnia patients and preparation method thereof | |
| CN103989712A (en) | Traditional Chinese medicine for treating facial paralysis and preparation method thereof | |
| CN104958504A (en) | Traditional Chinese medicine composition for preventing and treating sub-health and preparation method of traditional Chinese medicine composition | |
| CN104606636A (en) | Traditional Chinese medicine composition for treating depression and preparation method thereof | |
| CN101912466B (en) | Chinese patent medicament for treating eczema and dermatitis, relieving itching and stopping bleeding | |
| CN103550509B (en) | Chinese medicinal composition for treating lung-qi deficiency type night sweat | |
| CN102824624A (en) | Traditional Chinese medicine for treating bronchitis | |
| CN100406055C (en) | Chinese-medicinal preparation for treating hyposomnia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190118 |
|
| RJ01 | Rejection of invention patent application after publication |